Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study)

Peer Review reports

Original Submission
26 May 2021	Submitted	Original manuscript
10 Sep 2021	Reviewed	Reviewer Report - Yousuke Nakai
24 Sep 2021	Reviewed	Reviewer Report - Keith Roberts
26 Oct 2021	Author responded	Author comments - Tomohisa Yamamoto
Resubmission - Version 2
26 Oct 2021	Submitted	Manuscript version 2
17 Nov 2021	Reviewed	Reviewer Report - Keith Roberts
Resubmission - Version 3
	Submitted	Manuscript version 3
Publishing
23 Jan 2022	Editorially accepted
5 Feb 2022	Article published	10.1186/s13063-022-06049-7

Back to article page